Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar, aflibercept)

 Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar, aflibercept)

Shots:

  • BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy, safety and immunogenicity. Additionally, the design of the study is developed in collaboration with the USFDA, EMA, PMDA
  • The second program in ophthalmology will aim to strengthen and expand the footprints in ophthalmologic biosimilars
  • FYB203 is a biosimilar to Eylea (aflibercept) human fusion protein works by binding to VEGF-A, targeted for neovascular age-related macular degeneration (nAMD) including serious eye diseases. In 2015, Formycon AG signed an exclusive global license agreement with Santo Holding (Deutschland) GmbH for FYB203

Click here to read full press release/ article | Ref: Formycon | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post